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Abstract Diffuse malignant mesothelioma is an aggressive
tumor which displays a median survival of 11.2 months and
a 5-year survival of less than 5% emphasizing the need for
more effective treatments. This study uses an orthotopic
model of malignant mesothelioma established in syngeneic,
immunocompetent C57Bl/6 mice which produce malignant
ascites and solid tumors that accurately replicate the
histopathology of the human disease. Host stromal and
immune cell accumulation within malignant ascites and
solid tumors was determined using immunofluorescent
labeling with confocal microscopy and fluorescence-
activated cell sorting. An expression profile of cytokines
and chemokines was produced using quantitative real-time
PCR arrays. Tumor spheroids and solid tumors show
progressive growth and infiltration with host stromal and
immune cells including macrophages, endothelial cells, CD4
+
and CD8
+ lymphocytes, and a novel cell type, myeloid
derived suppressor cells (MDSCs). The kinetics of host cell
accumulation and inflammatory mediator expression within
the tumor ascites divides tumor progression into two distinct
phases. The first phase is characterized by progressive
macrophage and T lymphocyte recruitment, with a cytokine
profile consistent with regulatory T lymphocytes differenti-
ation and suppression of T cell function. The second phase is
characterized by decreased expression of macrophage che-
motactic and T-cell regulating factors, an increase in MDSCs,
and increased expression of several cytokines which stimu-
late differentiation of MDSCs. This cellular and expression
profile suggests a mechanism by which host immune cells
promote diffuse malignant mesothelioma progression.
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Diffuse malignant mesothelioma is an aggressive tumor
which is diagnosed at an advanced stage 20 to 60 years
following chronic asbestos exposure [1–3]. Diffuse malig-
nant mesothelioma most frequently arises in the pleural,
peritoneal or pericardial linings. Malignant ascites is
accompanied by solid tumor masses with extensive spread-
ing over the serosal surfaces and local invasion into the
lung parenchyma [4]. The prognosis for patients with
diffuse malignant mesothelioma is poor with a median
survival of 11.2 months and a 5-year survival of less than
5% [5]. Poor survival is due to the inability to achieve
complete surgical resection or eradication by radiotherapy
resulting in local tumor recurrence with pleural and
peritoneal seeding. Recent clinical studies using multi-
modality therapies combining radical surgery, multiple
agent chemotherapy, and radiotherapy to treat selected
patients have increased survival up to a median of
18.1 months with a 5-year survival of about 12%[6].
The failure of conventional surgical, chemotherapeutic,
or radiotherapy protocols directed towards the neoplastic
cells [7, 8] has motivated the exploration of alternative
therapeutic targets. Anti-angiogenic therapies, such as
vascular endothelial growth factor (VEGF) inhibitors, have
shown some efficacy in diffuse malignant mesothelioma
[9], but the most promising adjuvant therapy is immuno-
therapy. The combination of an activating anti-CD40
antibody [10, 11] or interleukin 2 (IL2) [12] with tumor
debulking surgery produces significant improvements in
survival with some rodent studies showing a resistance to
tumor re-challenge. More complete characterization of the
tumor microenvironment is necessary to identify additional
host targets for novel and less toxic therapeutic approaches.
The presence of host stromal and immune cells has been
linked to aggressive tumor growth, invasion, and metastasis
in several types of cancer [13]. The best documented
correlation is between density of tumor-associated macro-
phages and poor prognosis in 80% of epithelial cancers, as
well as in diffuse malignant mesothelioma [14, 15]. T-
lymphocytes, macrophages, NK cells, fibroblasts, and
dendritic cells have each been identified in human and
murine diffuse malignant mesotheliomas [16–18] with
studies showing that targeting T-lymphocytes [17, 19]o r
macrophages [14] delays tumor progression in murine
diffuse malignant mesothelioma.
Recruitment, regulation, and activation of host stromal
and immune cells is mediated by a complex network of
extracellular signals [20]. In the tumor microenvironment,
cytokines, angiogenic factors, and growth factors are
produced by both tumor and host cells [21, 22]. Human
pleural effusions and solid malignant mesotheliomas show
elevated expression of VEGF [17, 23], fibroblast growth
factor 2 (FGF2)[24], hepatocyte growth factor [25] and IL-
6[17, 26]. These factors stimulate mesothelioma cell growth
in vitro as well as angiogenesis in vivo [23, 27].
Immunoregulatory factors including transforming growth
factor-β (TGF-β)[28] and IL-10[29] have been shown to
reduce T-cell mediated killing of malignant mesothelioma
cells [30]. Diffuse malignant mesotheliomas show elevated
levels of several chemotactic factors, including CCL5,
which recruits macrophages, and CXCL12, which recruits
a variety of stromal and immune cells [17]. Alteration to the
tumor microenvironment by targeting key immunoregula-
tory factors and host immune cells has shown the potential
to deactivate tumor immunosuppression. Treatment of
ectopic murine malignant mesotheliomas with a TGF-β
receptor kinase inhibitor and interferon-β produces a
reduction in tumor growth, increases survival and alters
host tumor stromal and immune cells [31].
Despite the well-established causal relationship between
asbestos and diffuse malignant mesothelioma, cases of early
stage disease are extremely rare due to the long and
unpredictable latent period and the low incidence of
chronically exposed individuals developing the disease
[32]. Therefore, studies of early stage diffuse malignant
mesothelioma require use of animal models. Autochtho-
nous models of diffuse malignant mesothelioma accurately
replicate the natural history and pathology of the human
disease, but are unsuitable for most studies due to the long
latent period between exposure to asbestos fibers and tumor
development [33]. In this study, an orthotopic, immuno-
competent murine model is used to characterize the
peritoneal microenvironment throughout the course of
tumor growth and progression. This characterization of
the cellular and expressed microenvironment during tumor
progression has identified mediators which have the
potential to be critical targets for the development of novel
immunotherapies.
Methods
Cell Culture The malignant mesothelioma cell line, 40 L,
was derived from lung micrometastases developed in a
C57Bl/6 mouse following subcutaneous injection of the
primary, asbestos-induced mesothelioma cell line, 40,
reported in Goodglick et al. [34]. A non-tumorigenic,
immortalized, mesothelial cell line, D9, was derived from
a diaphragmatic explant following a single exposure to
asbestos as described in the same publication. The cell lines
were maintained in DMEM with 2 mM L-glutamine, 1 mM
sodium pyruvate, 10 units/ml penicillin and 10 μg/ml
streptomycin, 10 μg/ml gentamicin, 10% fetal bovine
serum in humidified atmosphere of 94% air/6% CO2 at
37°C.
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(bACT-eGFP) 10sb (eGFP) mice were purchased from
Jackson Laboratories. All eGFP mice were the offspring of
an in-house breeding colony. Mice were housed in sterile
rodent HEPA ventilated microisolators (Thoren Units) in a
facility approved by the American Association for Accred-
itation of Laboratory Animal Care that met all federal and
state animal care principles, guidelines and regulations. The
mice used were between 2 and 12 months of age.
Intraperitoneal Transplantation of Mesothelioma Cells In-
traperitoneal (i.p.) injection was used to deliver malignant
mesothelioma or immortalized mesothelial cells (2x10
6).
Mice were euthanized by CO2 asphyxiation and the organs
within the thorax and abdomen were harvested. Prior to
organ harvest, the peritoneum of eGFP mice, and some WT
mice, was perfused with 4% paraformaldehyde for 1 h.
Tissues were stored at −80°C in OCT blocks and sectioned
at 7–10 μm using a cryostat. Tissues from WT mice not
fixed in paraformaldehyde were removed at necropsy and
either fixed in 10% formalin for assessment of tissue
morphology or lysed for RNA and qRT-PCR expression
microarray. Tissues fixed in 10% formalin were paraffin
embedded, sectioned at 5 μm, and stained with hematox-
ylin and eosin (H&E).
Tumor spheroids were isolated by lavage from both
paraformaldehyde perfused and unfixed mouse peritoneum.
Ascitic cells and tumor spheroids were collected by low-
speed centrifugation and flash-frozen in liquid nitrogen for
RNA isolation, plated onto glass coverslips, or frozen in
OCT as cell blocks. Total RNAwas isolated from tissue and
lavage cells with TRI-reagent
® (Molecular Research Center,
Inc., Cincinnati, OH) or with RNeasy mini kit (QIAGEN
Inc., Valencia, CA) according to the manufacturer’s
protocol.
Reagents for Histology Tissues and tumor ascites were
harvested on days 7, 14, 21, and 28 following injection.
Tissues fixed in 10% formalin were paraffin embedded,
sectioned at 5 μm, and stained with H&E. Data was
compiled according to the day following cell injection and
are presented as the mean +/− SEM (N≥4 mice per group).
The number and size of tumors was assessed within
randomly selected, representative tissue sections using an
Axioplan microscope. Tumor ascites harvested following
injection with mesothelioma or mesothelial cells were
attached for 24 h on glass coverslips and stained with
May-Grünwald and Geimsa stains; frozen into OCT as a
1% agarose cell block, cryosectioned and immunofluores-
cent labeled; or lysed for RNA isolation. Micrographs of 5
randomly selected, fields on the May-Grünwald and
Geimsa stained slides were examined for each animal to
assess spheroid size. The data reported are the longest
diameter of 10 randomly selected spheroids from each of
three mice per time point. Brightfield micrographs of
stained cells were obtained using a Nikon Eclipse E800
microscope with a Spot RT color camera and software.
Reagents for Immunofluorescence Cryosectioned solid
tumors and tumor ascites containing spheroids were
immunofluorescently labeled for stromal and immune cell
markers. Immunolabeling used a primary antibody solution
containing one or two of the following: rat-anti mouse F4/
80 antigen, rat anti-mouse CD68, ALEXA 488-conjugated
hamster anti-CD11c, Rat anti-mouse CD4, Rat anti-mouse
CD8α, Alexa 488-conjugated Rat anti-mouse CD25, Alexa
488-conjugated Rat anti-mouse CD11b (ABD Serotec,
Raleigh, NC), Rat anti-mouse GR-1, Rat anti-mouse
CD117 (BD Pharmingen, San Diego, CA), ALEXA 488-
conjugated rat anti-CD144 (BD Pharmingen, San Diego,
CA), rabbit anti-eGFP (Chemicon International, Inc.,
Temecula, CA) in a blocking solution composed of 10%
normal sera matched to the species of the secondary
antibody, 0.1% Tween-20 and 0.1% bovine serum albumin
in phosphate buffered saline (PBS). After a 24 h incubation
at 4°C the tissue or cells were thoroughly rinsed and
incubated in a 5 μg/ml dilution of one or two of the
following: ALEXA 555-conjugated goat anti-rat, ALEXA
488-conjugated donkey anti-rabbit IgG or ALEXA 488-
conjugated donkey anti rat IgG (Invitrogen, Carlsbad, CA)
in blocking solution. Omission of the primary antibody was
performed in parallel for each sample and confirmed that
the observed fluorescence is specific. The tissues or cells
were then rinsed with PBS and mounted in Vectashield
®
hardset containing DAPI (Vector Laboratories, Burlingame,
CA). Apoptosis was assessed by TUNEL assay (Roche
Diagnostics, Indianapolis, IN) or by nuclear condensation
and fragmentation assessed by light microscopy. Confocal
fluorescent micrographs were created using a Zeiss 410
confocal laser scanning microscope (Carl Zeiss, Inc.,
Thornwood, NY) with Phoenix version 2.0 software
(Microcosm, Inc., Columbia MD).
Profile of Tumor Ascites Cells During Mesothelioma Cell-
Derived Tumor Formation Tumor spheroids were separated
from tumor ascites using low speed (500 RPM for 5 min)
centrifugation and dissociated into single cell suspension
with collagenase/trypsin and agitation. The “free cell” and
“spheroids-associated” cell fractions were paraformalde-
hyde fixed and immunofluorescently labeled to identify
stromal and immune cells as described above. Paired
unstained samples were used as negative controls.
Fluorescence-activated cell sorting (FACS) was performed
to profile the ascitic cells over the time course of tumor
spheroid formation. A FACSCalibur
TM system (Becton
Dickinson, San Jose, CA) was used for sorting and CELL
Host cell recruitment in malignant mesothelioma 41Quest software (Becton Dickinson) was used to perform the
analysis. Data were compiled temporally and the fraction of
the total cells composed by each cell type for each mouse
(N ≥2 mice per group) is displayed.
RT² Profiler™ PCR Arrays Total RNA (1 μg) was
harvested from peritoneal exudate cells before (resident
peritoneal cells), 7, 14 and 21 days following i.p. injection
of mesothelioma cells, from solid tumors harvested 21 days
following i.p. injection, as well as from mesothelioma and
mesothelial cells grown in vitro. A quantitative real-time
PCR array was used to screen inflammatory cytokines and
receptors (Cat. No. PAMM-011), angiogenic factors (Cat.
No. PAMM-024) and tumor metastasis-related transcripts
(Cat. No. PAMM-028) according to the manufacturer’s
instructions (SuperArray Bioscience, Frederick, MD).
Reactions were cycled in an ABI Prism® 7500 FAST
sequence detector (Applied Biosystems, Inc., Foster City,
CA) and the acquired data was analyzed to determine the
relative expression level of each transcript after normaliza-
tion to the expression level of housekeeping gene controls.
Statistics All data, excepting the FACs data, were
calculated as the mean±SE. The number and area of
tumors were determined using representative tissue
sections from each of seven sites within the peritoneal
cavity. The sum of all tumor areas within each mouse is
expressed as the total tumor burden. Statistical signifi-
cance was assessed using the following methods with
differences with P<0.05 being considered statistically
significant. The significance of variations within the
increasing trend to spheroid size, tumor frequency and
tumor burden was assessed by linear regression or Poisson
regression (Figs. 1 and 2). Significant changes in expression
over time (Fig. 5) were determined using a moderated t-test
[35] with significance level 0.01(Benjamini-Hochberg false
discovery rate).
Results
Pathology of Transplanted Murine Malignant
Mesothelioma
Orthotopic transplantation of an asbestos-induced mesothe-
lioma cell line into the peritoneum of syngeneic mice
reproducibly produces tumor ascites, tumor spheroids, and
solid tumors that re-capitulate the human disease (Figs. 1
and 2). As early as 7 days following intraperitoneal
injection of mesothelioma cells, tumor spheroids (Fig. 1b)
and microscopic tumor masses are established (Fig. 2b, first
panel). Multicellular spheroids are present both before and
after formation of solid tumors indicating a potential role in
both tumor establishment and the spread of tumor on the
serosal surfaces. Early solid tumors (Fig. 2b, third panel)
are microscopic aggregates of tumor and host stromal cells
that attach to the mesothelial lining. Vascularized tumor
masses attach on the inferior surface of the diaphragm and
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Fig. 1 Kinetics of tumor spher-
oid growth. a. Average area
of tumor spheroids within
malignant ascites over time±
SEM (N≥30). b. Representative
spheroids shown by cell type
and time point (Bar=100 um)
with a representative image of
apoptotic cells (Bottom, fourth
panel; Bar=50 um)
42 N.R. Miselis et al.on the mesentery. After 21 days, solid tumor masses display
invasive growth penetrating into the parenchyma of
abdominal organs (Fig. 2b, fourth panel).
The distinct and reproducible pattern of tumor seeding,
implantation, and invasion makes this tumor model well
suited for kinetic studies of the tumor microenvironment
during tumor progression. Injection of malignant mesothe-
lioma cells produces spheroids which grow progressively
up to 21 days when the average size nears 0.1 mm
2
(Fig. 1a, black bars) and a characteristic necrotic core forms
at the center of the tumor spheroids (data not shown). In
contrast immortalized, non-tumorigenic mesothelial cells
form very small aggregates that disappear after 14 days
(Fig. 1a, white bars). The inability of immortalized, non-
tumorigenic mesothelial cells to form viable cell aggregates
corresponds with a higher incidence of apoptosis when
compared to injection of malignant mesothelioma cells, 8-
times greater at day 7 (3.2% vs. 0.4), 2-times greater at day
14 (1.4% vs. 0.7%), and more than 4-times greater at day
21 (3.3% vs. 0.7%).
The kinetics of solid tumor establishment and growth is
different from that of tumor spheroids. The frequency of solid
tumors within the peritoneal cavity gradually increases
throughout 28 days (Fig. 2a, top), while the total tumor area
(tumor burden) shows a delayed progression (Fig. 2a,
bottom). Between 7 and 14 days post-tumor cell injection
the tumor burden increases 2-fold from 2.1 mm
2 to 5.4 mm
2
with a similar 2-fold increase between days 21 and 28;
however between day 14 and 21 the tumor burden increases
8-fold from 5.4 mm
2 to 43.9 mm
2. During this accelerated
phase of tumor development, there is increased tumor
invasion into adjacent tissues (Fig. 2b, fourth panel) followed
by development of pulmonary metastases [14].
Identification of Host Stromal and Immune Cells
in Spheroids and Solid Tumors
Similartothehumandisease[16–18], this tumor model shows
infiltration of host stromal and immune cells into both tumor
spheroids and solid tumors. Transplantation of mesothelioma
cells into eGFP mice reveals a significant proportion of host
cells in both tumor spheroids (Fig. 3a, first panel) and solid
tumors (Fig. 3b, first panel). Immunofluorescent labeling of
spheroids and tumors established in wild-type mice identifies
b. Day 7 Day 14  Day 14 Day 21
Fig. 2 Kinetics of tumor mass
dissemination and growth.
a. Average tumor frequency (top)
and tumor burden (bottom)
following mesothelioma cell in-
jection. Each mean was
calculated from at least three
mice and is shown±SEM. b.
Representative images of tumor
growth and progression. Free-
floating tumor spheroids (second
panel) are composed of malig-
nant (circles) and host stromal
cells (arrowheads). Tumor
masses show a progressive pat-
tern of tumor establishment (first
panel), growth (third and fourth
panels) and invasion into adja-
cent tissues (fourth panel). H&E
stain
Host cell recruitment in malignant mesothelioma 43diffusely distributed tumor-associated macrophages (Fig. 3a
and b, second panels) and endothelial cells which are present
in tumor spheroids as isolated cells that form an extensive
vascular network in solid tumors (Fig. 3a and b, third panel).
Myeloid-derived suppressor cells (MDSCs), identified by
GR-1 (red fluorescence) and CD11b (green fluorescence)
expression, are present in spheroids but are less frequent in
solid tumors (Fig. 3a and b, fourth panel, arrowheads). Other
immune cells, albeit at low density, include dendritic cells
(Fig. 3c and d, first panel), CD4
+,C D 2 5
+ lymphocytes
All Stromal cells        Tumor-Associated Macrophages        Endothelial cells  MDSCs 
a.
b.
Dendritic Cells            Regulatory T lymphocytes     Cytotoxic T lymphocytes   Haemotopoietic stem cells
c.
d.
(eGFP)
(CD11c) (CD4 & CD25) (CD3 & CD8) (CD117)
(F4/80) (CD144) (CD11b & GR-1)
Fig. 3 Host stromal cells in tumor spheroids and solid tumors.
Identification of host cells within tumor spheroids (a, c) and solid
tumors (b, d). Indirect immunofluorescent labeling for eGFP identifies
host-derived cells, F4/80 identifies macrophages and CD144 identifies
endothelial cells. Expression of CD11b and GR-1 identifies myeloid-
derived suppressor cells (white arrowheads), CD11c identifies
dendritic cells, CD4 and CD25 identifies regulatory T lymphocytes,
and CD3 and CD8 identifies cytotoxic T lymphocytes. Following
immunolabeling, tissues were counterstained with DAPI and assessed
by confocal microscopy at 600x magnification
44 N.R. Miselis et al.(Fig. 3c and c, second panel) and CD8
+ lymphocytes (Fig. 3c
and d, third panel) and haematopoietic stem and/or endothe-
lial progenitor cells (Fig. 3c and d, fourth panel). In each
panel, omission of the primary antibody did not produce
fluorescent labeling (data not shown).
Host Stromal and Immune Cell Recruitment
to the Peritoneal Cavity and Tumor Spheroids
The presence of host stromal cells within peritoneal
tumor spheroids suggests that these cells facilitate tumor
spheroid formation, tumor cell survival and growth;
therefore, the kinetics of host cell recruitment to tumor
ascites and tumor spheroids was examined. Free-floating
single cells and tumor spheroid-associated cells were
separated from peritoneal lavage fluid and examined by
FACS analysis (Fig. 4). Macrophages are the predominant
host cell type in recovered ascitic fluid, 45.5%, and in
spheroids, 27%, at 21 days post injection (Fig. 4a).
Endothelial cells are present early in the ascitic fluid but
decline rapidly and increase to a maximum of 15% in
tumor spheroids at 21 days (Fig. 4b). Dendritic cells
Fig. 4 A quantitative profile of
the host cell population within
peritoneal effusions and tumor
spheroids throughout tumor
progression. Free-floating single
cells and dissociated spheroid-
associated cells were harvested
at 7 day intervals from 2 repli-
cate mice and analyzed by flow
cytometry to determine the pro-
portion of (a) macrophages, (b)
endothelial cells and (c) myeloid
derived suppressor cells. The
graphs show the data from each
mouse (■) and a mean of the
replicates (▬)
Host cell recruitment in malignant mesothelioma 45constitute less than 3% of cells at all time points in both
groups (data not shown). In contrast, MDSCs constitute
45% of the ascitic cells after 7 days, but are not present in
tumor spheroids until 14 days (Fig. 4c). The proportion of
MDSCs within tumor spheroids shows a progressive
increase to a maximum of 47% after 28 days (Fig. 4c).
This trend closely mirrors that of tumor burden (Fig. 2a,
bottom) suggesting that spheroid-associated MDSCs could
facilitate tumor growth.
Kinetics of Chemokine and Cytokine Expression in Tumor
Ascites
To determine the kinetics of host cell recruitment to
developing tumors, the gene expression profile of chemo-
kines, cytokines and growth factors was determined
throughout tumor establishment and progression (Fig. 5).
The expression profile of tumor ascites harvested 7, 14 and
21 days post-injection was compared to the malignant
mesothelioma cell line in vitro, immmortalized mesothelial
cells in vitro, and resident peritoneal cells (Supplemental
Table 1). The relative expression is derived from the Ct
values of three biological replicates normalized to the
average level of expression for multiple housekeeping
genes.
Many chemokines associated with recruitment of host
immune cells showed elevated expression as compared to
malignant mesothelioma cells in vitro (Fig. 5a and
Supplemental Table 1). The most highly expressed chemo-
kines are CCL5, CCL6, and CCR2 which mediate
recruitment of monocytes in addition to lymphocytes.
Regulatory T lymphocytes have been suggested to facilitate
diffuse malignant mesothelioma progression [17]. While
ascitic cells show low expression of CCL20, CCR8, CCL22
and CCR7, there is significantly elevated expression of
CCL24 and IL-16 after 7 days with a significant reduction
after 14 days(Fig. 5a and Supplemental Table 1).
Many macrophage chemotactic factors are upregulated
throughout the course of tumor progression [14]. The most
highly expressed chemotactic factors within the tumor
ascites are CCL6 and CCL9 with CCL2, CCL5 and
CXCL2 showing small increases in expression as compared
to the malignant mesothelioma cell line in vitro (Fig. 5a and
Supplemental Table 1). The receptors for these cytokines
also show greater expression in ascitic cells. CCR1, a
receptor for CCL5, CCL6 and CCL9, CCR2, the receptor
for CCL2, and CCR5, another receptor for CCL5, all show
a significant increase in expression when compared to
malignant mesothelioma or immortalized mesothelial cells
in vitro (Supplemental Table 1). The chemokines and
Fig. 5 Profile of angiogenic and inflammatory mediators expressed
within peritoneal tumor ascites during tumor progression. Transcripts
are grouped by function (a) and time of peak expression (b). The
relative level of expression for each group is displayed graphically and
is defined as the 2^-ΔCt values +/− SEM; N=3
46 N.R. Miselis et al.cytokines CCL22, CCL24, CXCL5, IL1b, IL6 and IL10
which are expressed by macrophages show low expression,
but is greater than that of malignant mesothelioma or
immortalized mesothelial cells in vitro (Fig. 5a and
Supplemental Table 1).
Several factors which regulate endothelial cell recruit-
ment are expressed in ascitic cells. The most highly
expressed is the anti-angiogenic chemokine CXCL4 which
shows a statistically significant trend of decreasing expres-
sion throughout tumor progression (Fig. 5a and Supple-
mental Table 1). The chemokines CXCL2 and CXCL5
show low levels of expression in tumor ascites which are
greater than that of the malignant mesothelioma cell line in
vitro (Fig. 5a and Supplemental Table 1). Several chemo-
kines for immature myeloid cells and MDSCs are also
expressed. As discussed previously, CCL5, CCL6, CCL9,
and CXCL5 all showed elevated expression, as did one of
the complementary receptors, CCR1.
To assess the kinetics of stromal cells recruitment,
transcripts were grouped temporally according to the time
of peak expression (Fig. 5b). Transcripts with highest
expression after 7 days include CCR1, CXCL4, CXCL13,
CXCR5, IL16, TGFβ1, TGFβ2 and Thbs1, but also genes
that show a rapid decrease, such as CCL24. By day 14 the
chemokines that show peak expression are primarily
monocyte chemokines and macrophage-derived cytokines
(CCL2, CCL5, CCL6, CCL7, CCL17, CCL22, CXCR2,
IL1β, IL6, SPP1 and VEGFA) and the majority of these
chemokines and cytokines show a drop in expression after
21 days(Fig. 5b and Supplemental Table 1). This occurs in
conjunction with a decrease in macrophages and increased
tumor burden by day 28 (Fig. 4). An inverse trend is
observed for the majority of chemokines and cytokines
which show their highest level of expression at day 21.
CCL9, CCR2, CCR3, CCR5, Ctgf, CXCL12, Fgf1, MMP2,
TGFβ3, Tnfrsf1a and Tnfrsf1b each show their lowest
expression at day 14 and all except CCL9 peak at day 21
(Fig. 5b and Supplemental Table 1). To confirm that these
alterations in gene expression corresponded with protein
expression and secretion a protein array was performed
using peritoneal lavage fluid. Six cytokines, CCL2, CCL5,
CCL12, CXCL1, IL-1α and IL-6, peaked at 14 days in
agreement with their gene expression profiles.
Gene Expression Profiles of Murine and Human Diffuse
Malignant Mesotheliomas
To evaluate the similarity in the microenvironment within
tumor spheroids and solid tumors, the entire expression
profiles of cytokines and their receptors were compared.
Similar up- or down-regulation was identified for 85% of
the transcripts (71 of 84) when shown relative to the
mesothelioma cell line in vitro (Fig. 6a). The expression
profiles of human diffuse malignant mesotheliomas are
highly variable; however, a profile of 64 cytokine, cytokine
receptor and metastasis-related transcripts was used to
compare the microenvironment of murine malignant meso-
thelioma after 21 days with human epithelial diffuse
malignant pleural mesotheliomas whose expression profile
was reported in Mohr, S. et al. [36]. Similar to our
comparison of tumor spheroids and solid tumors, these
authors compare expression in human malignant mesothe-
liomas to cell lines in vitro. This analysis shows that 66%
of the transcripts (42 of 64) within murine diffuse
malignant mesotheliomas display similar alterations in
expression compared to human epithelial diffuse malignant
pleural mesotheliomas (Fig. 6b).
b
Fig. 6 Alignment of tumor and ascites expression profiles. a.
Expression of cytokines, chemokines and their receptors within murine
tumors and tumor ascites at 21 days shows similar up- or down-
regulation relative to the mesothelioma cell line in vitro; N ≥2. b.
Human malignant mesotheliomas and murine malignant mesotheliomas
show similar regulation of chemokines, cytokines and metastasis-related
transcripts relative to species matched cell lines in vitro; N ≥1
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This model of transplanted diffuse malignant mesothelioma
shows the formation of malignant ascites, tumor masses and
secondary pulmonary metastases similar to autochthonous
models of diffuse malignant mesothelioma in rodents and
the human disease [19, 34, 37–39] (Figs. 1 and 2). Despite
being of murine in origin, the combination of similar
disease pathology and gene expression profile (Fig. 6)
validates that these orthotopically transplanted diffuse
malignant mesotheliomas reflect the microenvironment of
the human disease. Using this tumor model, we showed
previously that depletion of tumor-associated macrophages
significantly reduces tumor growth and metastasis [14]. By
profiling host cell recruitment throughout the course of
tumor progression, an additional myeloid-derived cell
population not previously described in diffuse malignant
mesotheliomas was identified: MDSCs. The parallel be-
tween increasing tumor burden (Fig. 2a, bottom) and
accumulation of MDSCs within tumor spheroids (Fig. 4c)
suggests that MDSCs accelerate tumor progression.
MDSCs have been reported to mediate the suppression of
host acquired immunity and stimulation of tumor growth in
other tumor models [40–43] suggesting that MDSCs are
participating in the establishment of an immunosuppressive
tumor microenvironment in this tumor model.
The presence of MDSCs within tumor spheroids and
solid tumors of animals with advanced stage disease
identifies this cell type a potential mediator of the non-
immunogenic phenotype of this tumor. MDSCs have been
shown to inhibit CD4+ and CD8+ T cell proliferation [42],
block natural killer cell activation [43], limit dendritic cell
maturation [41] and polarize macrophage towards an M2
phenotype both with and without TGF-β expression [44–
46]. These data suggest strategies that target not only T
lymphocytes, but also macrophages and myeloid-derived
suppressor cells could enhance host cell-mediated immune
destruction of malignant mesotheliomas.
These results also support a role for regulatory T cells in
suppressing immune responses as proposed by Hegmans et
al. 2006 in their study of mouse and human malignant
mesotheliomas [17]. Regulatory T lymphocytes are found
within tumor spheroids and solid tumors (Fig. 3c and d,
third panels) and appear to be actively recruited and
regulated by host chemokines (Figs. 5 and 7a). The
majority of lymphocyte chemotactic factors show their
highest expression 7 days following injection of tumor
cells. CCL24, which recruits resting T lymphocytes while
also suppressing their Th1 immune responses [47], peaks at
7 days. IL-16, which is frequently present in malignant
pleural effusions, attracts T lymphocytes and stimulates
CD25 expression during differentiation to regulatory T
lymphocytes [48], also shows a peak at 7 days (Fig. 5b).
The cytokine profile of the microenvironment within the
peritoneal cavity at this early stage of tumor development is
composed of chemokines responsible for recruiting lym-
phocytes, monocytes, and establishing a local immunosup-
pressive environment (Figs. 5 and 7a). This evidence
suggests that following injection regulatory T lymphocytes
establish an environment of immunotolerance allowing
persistence of malignant mesothelioma cells.
This cytokine profile also reveals a prominent role for
macrophages. The profile aligns with that of a myeloid-
enriched tumor “stromal” profile as described by Lenz, et
al.[49]. Increased expression of Ctgf, Itgb2, TGFβ1,
Thrombospondin 1 and TIMP2 and decreased expression
of Kdr, PECAM1, or TEK is consistent with a myeloid-
enriched profile rather than an endothelial cell-enriched
profile (Fig. 5 and Supplemental Table 1). This character-
ization is supported by the cellular profile which shows a
Fig. 7 Regulation of the tumor
microenvironment. Expressed
mediators which participate in
the recruitment and regulation of
stromal and immune cells at a.
14 days b. 21 days post tumor
cell injection
48 N.R. Miselis et al.prominent macrophage population throughout tumor pro-
gression (Fig. 4a) and the expression profile of monocyte
chemotactic factors CCL9, showing peak expression at
7 days, and CCL2, CCL7 and CCL12, that show both
statistically significant patterns of expression and peak
expression at day 14 (Fig. 5b). A role for macrophages is
suggested by the expression of factors which mediate
macrophage—lymphocyte interactions (Fig. 5b). For ex-
ample, the macrophage-derived chemokines, CCL17 and
CCL22, which show peak expression at day 14, recruit Th2
and regulatory T-cells and in combination with CCL2
stimulate naïve and resting T lymphocytes to become
regulatory T lymphocytes [20, 50, 51] suggesting that
macrophages mediate the recruitment and regulation of T
lymphocytes (Fig. 7a).
The cytokine profile three weeks after injection charac-
terizes a microenvironment that suppresses immune sur-
veillance and antitumor immunity (Fig. 7b). CXCL12, a
chemotactic factor for MDSC [17], peaks after three weeks.
In combination with elevated expression of CCL9 [52] and
CXCL5[46] this profile could mediate the substantial
increase in MDSCs observed after 3 to 4 weeks (Figs. 4
and 5b).
This publication is the first to present a comprehen-
sive expression profile of the tumor microenvironment
throughout the progression of diffuse malignant meso-
thelioma in a murine orthotopic model. This model was
validated by comparing the expression profile of human
diffuse malignant mesotheliomas and transplanted murine
malignant mesotheliomas which revealed 66% of the
transcripts display similar patterns of expression when
compared to species-matched mesothelioma cell lines in
vitro (Fig. 6b). The common transcripts describe a
microenvironment that actively recruits MDSCs, macro-
phages and T lymphocytes. The macrophage and MDSC-
chemotactic factors, CCL1, CCL5, CCL6, and their
receptors CCR1 and CCR5 showed similar regulation in
both the human and murine malignant mesotheliomas in
addition to T lymphocyte chemotactic factors CCL1,
CCL5, CCL6, and CCL17. These results validate that this
murine model of diffuse malignant mesothelioma repli-
cates the human host stromal and immune microenviron-
ment potentially identifying critical cellular targets for
novel adjuvant therapies.
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